Details

α-Aminoboronic acid moieties in boro dipeptides modulate proteasome subunit selectivity and provide access to compounds with potent anticancer and anti-inflammatory activity
ID Strašek Benedik, Nika (Author), ID Šterman, Andrej (Author), ID Smrdel, Lara (Author), ID Pajk, Stane (Author), ID Gobec, Stanislav (Author), ID Časar, Zdenko (Author), ID Gobec, Martina (Author), ID Sosič, Izidor (Author)

.pdfPDF - Presentation file, Download (3,13 MB)
MD5: 1E9D1F9D12D18D032B5808BADF8CFCC4
URLURL - Source URL, Visit https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c02548 This link opens in a new window

Abstract
Proteasomes regulate cellular protein homeostasis and are key targets in treating cancer, inflammation, and autoimmune diseases. The two main forms, the constitutive proteasome and immunoproteasome, each contain three catalytically active subunits with distinct substrate specificities. The first approved proteasome inhibitor, bortezomib, is nonselective and causes dose-limiting toxicity. Herein, we report dipeptide boronic acids with varying P1 residues, prepared using our recently developed method for α-aminoboronic acids formation. Most compounds inhibited various immuno/proteasome subunits in the low nanomolar range, displaying inhibition profiles distinct from bortezomib, ranging from β5i/β1i-selective to β5c/β5i-directed inhibitors. Although their cytotoxicity to cancer cells was not improved compared to bortezomib, selected compounds proved less toxic to noncancer cells and with anti-inflammatory activity comparable to that of zetomipzomib (KZR-616). The presented boro dipeptides with tailored P1 residues provide a basis for designing subunit-selective compounds with boronic acid as the warhead and optimized P2 and/or P3 positions.

Language:English
Keywords:proteasomes, homeostasis, cellular proteins, anticancer activity, anti-inflammatory activities, cells, inhibition, inhibitors, peptides, proteins, screening assays
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:Str. 26405−26417
Numbering:Vol. 68, iss. 24
PID:20.500.12556/RUL-177836 This link opens in a new window
UDC:543.2/.9
ISSN on article:1520-4804
DOI:10.1021/acs.jmedchem.5c02548 This link opens in a new window
COBISS.SI-ID:260217091 This link opens in a new window
Publication date in RUL:09.01.2026
Views:573
Downloads:418
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of medicinal chemistry
Shortened title:J. med. chem.
Publisher:American Chemical Society
ISSN:1520-4804
COBISS.SI-ID:512806681 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:proteasomi, homeostaza, celične beljakovine, antikancerogeno delovanje, protivnetno delovanje, farmacevtska kemija, citologija, celična fiziologija, antionkogeni, protivnetna zdravila

Projects

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J3-50116
Name:Srčne skrbi: osvetlitev mehanizmov kardiotoksičnosti proteasomskih zaviralcev

Funder:ARIS - Slovenian Research and Innovation Agency
Project number:J1-50037
Name:Razvoj selektivnih razgrajevalcev CDK1 za zdravljenje T-celičnih malignih obolenj

Funder:ARIS - Slovenian Research and Innovation Agency
Funding programme:Young researchers

Funder:EC - European Commission
Funding programme:European Regional Development Fund
Project number:OP20.05187
Acronym:RI-SI-EATRIS

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back